Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth

Yujun Dong, Jiahua Qian, Ramy Ibrahim, Jay A. Berzofsky, Samir N. Khleif

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Vascular endothelial growth factor receptor 2 (VEGFR2/KDR) plays a crucial role in tumor-associated angiogenesis and vascularization. It has been established that monoclonal antibodies against VEGFR2 can inhibit angiogenesis. In this study, two naturally processed CD8 T-cell epitopes (VILTNPISM and FSNSTNDILI) were identified from murine KDR. Cytotoxic T lymphocytes targeting endothelial cells could be directly monitored by KDR2 and KDR3 Elispots or major histocompatibility complex class I tetramer staining. Immunization with these two peptides effectively reduced angiogenesis and inhibited tumor growth in mouse models. Thus, vaccination with KDR peptides alone or in combination with other anti-angiogenesis agents may afford a novel immunotherapy for inhibition of tumor growth.

Original languageEnglish (US)
Pages (from-to)32-40
Number of pages9
JournalJournal of Immunotherapy
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2006

Fingerprint

T-Lymphocyte Epitopes
Growth
Vascular Endothelial Growth Factor Receptor-2
Neoplasms
Peptides
Cytotoxic T-Lymphocytes
Major Histocompatibility Complex
Immunotherapy
Immunization
Vaccination
Endothelial Cells
Monoclonal Antibodies
Staining and Labeling

Keywords

  • Angiogenesis
  • Cancer vaccine
  • Cytotoxic T lymphocytes
  • Immunotherapy
  • MHC Class 1 epitopes
  • VEGFR2 (FLK-1, KDR)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. / Dong, Yujun; Qian, Jiahua; Ibrahim, Ramy; Berzofsky, Jay A.; Khleif, Samir N.

In: Journal of Immunotherapy, Vol. 29, No. 1, 01.01.2006, p. 32-40.

Research output: Contribution to journalArticle

Dong, Yujun ; Qian, Jiahua ; Ibrahim, Ramy ; Berzofsky, Jay A. ; Khleif, Samir N. / Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. In: Journal of Immunotherapy. 2006 ; Vol. 29, No. 1. pp. 32-40.
@article{3c04dd189f264359bfd00fb4bd20328b,
title = "Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth",
abstract = "Vascular endothelial growth factor receptor 2 (VEGFR2/KDR) plays a crucial role in tumor-associated angiogenesis and vascularization. It has been established that monoclonal antibodies against VEGFR2 can inhibit angiogenesis. In this study, two naturally processed CD8 T-cell epitopes (VILTNPISM and FSNSTNDILI) were identified from murine KDR. Cytotoxic T lymphocytes targeting endothelial cells could be directly monitored by KDR2 and KDR3 Elispots or major histocompatibility complex class I tetramer staining. Immunization with these two peptides effectively reduced angiogenesis and inhibited tumor growth in mouse models. Thus, vaccination with KDR peptides alone or in combination with other anti-angiogenesis agents may afford a novel immunotherapy for inhibition of tumor growth.",
keywords = "Angiogenesis, Cancer vaccine, Cytotoxic T lymphocytes, Immunotherapy, MHC Class 1 epitopes, VEGFR2 (FLK-1, KDR)",
author = "Yujun Dong and Jiahua Qian and Ramy Ibrahim and Berzofsky, {Jay A.} and Khleif, {Samir N.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1097/01.cji.0000175494.13476.56",
language = "English (US)",
volume = "29",
pages = "32--40",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth

AU - Dong, Yujun

AU - Qian, Jiahua

AU - Ibrahim, Ramy

AU - Berzofsky, Jay A.

AU - Khleif, Samir N.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Vascular endothelial growth factor receptor 2 (VEGFR2/KDR) plays a crucial role in tumor-associated angiogenesis and vascularization. It has been established that monoclonal antibodies against VEGFR2 can inhibit angiogenesis. In this study, two naturally processed CD8 T-cell epitopes (VILTNPISM and FSNSTNDILI) were identified from murine KDR. Cytotoxic T lymphocytes targeting endothelial cells could be directly monitored by KDR2 and KDR3 Elispots or major histocompatibility complex class I tetramer staining. Immunization with these two peptides effectively reduced angiogenesis and inhibited tumor growth in mouse models. Thus, vaccination with KDR peptides alone or in combination with other anti-angiogenesis agents may afford a novel immunotherapy for inhibition of tumor growth.

AB - Vascular endothelial growth factor receptor 2 (VEGFR2/KDR) plays a crucial role in tumor-associated angiogenesis and vascularization. It has been established that monoclonal antibodies against VEGFR2 can inhibit angiogenesis. In this study, two naturally processed CD8 T-cell epitopes (VILTNPISM and FSNSTNDILI) were identified from murine KDR. Cytotoxic T lymphocytes targeting endothelial cells could be directly monitored by KDR2 and KDR3 Elispots or major histocompatibility complex class I tetramer staining. Immunization with these two peptides effectively reduced angiogenesis and inhibited tumor growth in mouse models. Thus, vaccination with KDR peptides alone or in combination with other anti-angiogenesis agents may afford a novel immunotherapy for inhibition of tumor growth.

KW - Angiogenesis

KW - Cancer vaccine

KW - Cytotoxic T lymphocytes

KW - Immunotherapy

KW - MHC Class 1 epitopes

KW - VEGFR2 (FLK-1, KDR)

UR - http://www.scopus.com/inward/record.url?scp=33644822843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644822843&partnerID=8YFLogxK

U2 - 10.1097/01.cji.0000175494.13476.56

DO - 10.1097/01.cji.0000175494.13476.56

M3 - Article

VL - 29

SP - 32

EP - 40

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 1

ER -